Product datasheet
Anti-KALRN antibody ab52012
5 Abreviews 1 References 3 Images
Overview
Product name
Anti-KALRN antibody
Description
Goat polyclonal to KALRN
Specificity
This antibody is expected to recognize isoform 2 (NP_003938.1).
Tested applications
WB, ELISA, IHC-Fr, IHC-P
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat
Immunogen
Synthetic peptide:
C-RWHLGPGDPFSTYV
, corresponding to C terminal amino acids 1650-1663 of Human KALRN
Run BLAST with
Positive control
Run BLAST with
Mouse Brain lysate.
Properties
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage buffer
Preservative: 0.02% Sodium Azide
Constituents: 0.5% BSA, Tris saline, pH 7.3
Purity
Immunogen affinity purified
Clonality
Polyclonal
Isotype
IgG
Applications
Our Abpromise guarantee covers the use of ab52012 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application
WB
Abreviews
Notes
Use a concentration of 0.5 - 1.5 µg/ml. Detects a band of approximately 180 kDa
(predicted molecular weight: 192 kDa).
1
Application
ELISA
Abreviews
Notes
Use at an assay dependent concentration. Peptide ELISA: antibody detection
limit dilution 1:8000.
IHC-Fr
1/200.
IHC-P
Use at an assay dependent concentration.
Target
Function
Promotes the exchange of GDP by GTP. Activates specific Rho GTPase family members,
thereby inducing various signaling mechanisms that regulate neuronal shape, growth, and
plasticity, through their effects on the actin cytoskeleton. Induces lamellipodia independent of its
GEF activity.
Tissue specificity
Isoform 2 is brain specific. Highly expressed in cerebral cortex, putamen, amygdala,
hippocampus and caudate nucleus. Weakly expressed in brain stem and cerebellum. Isoform 4
is expressed in skeletal muscle.
Involvement in disease
Genetic variation in KALRN is associated with susceptibility to coronary heart disease type 5
(CHDS5) [MIM:608901]. CHD is the leading cause of death and disability worldwide. CHD is
multifactorial disease with a strong genetic component. Classic epidemiologic studies have
revealed many risk factors for CHD, including age, sex, hypertension, dyslipidemia, diabetes
mellitus, smoking, and physical inactivity.
Sequence similarities
Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family.
Contains 1 CRAL-TRIO domain.
Contains 2 DH (DBL-homology) domains.
Contains 1 fibronectin type-III domain.
Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 2 PH domains.
Contains 1 protein kinase domain.
Contains 2 SH3 domains.
Contains 5 spectrin repeats.
Domain
The two GEF domains catalyze nucleotide exchange for RAC1 and RhoA which are bound by
DH1 and DH2 respectively. The two GEF domains appear to play differing roles in neuronal
development and axonal outgrowth. SH3 1 binds to the first GEF domain inhibiting GEF activity
only when in the presence of a PXXP peptide, suggesting that the SH3 domain/peptide
interaction mediates binding to GEF1. CRK1 SH3 domain binds to and inhibits GEF1 activity.
Post-translational
modifications
Autophosphorylated.
Cellular localization
Cytoplasm. Cytoplasm > cytoskeleton. Associated with the cytoskeleton.
Anti-KALRN antibody images
2
ab52012 staining KALRN in adult brain tissue
by Immunohistochemistry (paraffin embedded
sections). Tissue was fixed with
paraformaldehyde and a heat mediated
antigen retrieval step performed using citrate
buffer. Tissues were then blocked with 15%
serum for 45 minutes at 20°C followed by
incubation with the primary antibody, at a
1/250 dilution, for 24 hours at 4°C. A Biotinconjugated rabbit anti-goat IgG was used as
secondary antibody at a 1/250 dilution.
Immunohistochemistry (Formalin/PFA-fixed
Upper image: Un-treated.
paraffin-embedded sections) - KALRN antibody
(ab52012)
Lower image: Treated with peptide to
Image kindly supplied by Dr Janine Magg through
Abreview
KALRN.
Counterstained with Hämalaun.
3
All lanes : Anti-KALRN antibody (ab52012)
at 1/500 dilution
Lane 1 : Whole tissue lysate prepared from
mouse brain, treated with peptide.
Lane 2 : Whole cell lysate prepared from
mouse brain cells over-expressing KALRN
(with FLAG-tag) treated with peptide.
Lane 3 : Whole cell lysate prepared from
mouse brain cells over-expressing KALRN,
Western blot - KALRN antibody (ab52012)
with FLAG-tag, detected with anti-FLAG
antibody.
Lane 4 : Whole tissue lysate prepared from
mouse brain
Lane 5 : Whole cell lysate prepared from
mouse brain cells over-expressing KALRN,
with FLAG-tag.
Lysates/proteins at 30 µg per lane.
Secondary
Donkey anti-goat IgG conjugated to HRP at
1/10000 dilution
developed using the ECL technique
Performed under non-reducing conditions.
Predicted band size : 192 kDa
Observed band size : 192 kDa
Exposure time : 1 minute
Image kindly supplied by Dr Janine Magg
through Abreview
Anti-KALRN antibody (ab52012) at 0.5 µg/ml
+ Mouse Brain lysate in RIPA buffer at 35 µg
developed using the ECL technique
Performed under reducing conditions.
Predicted band size : 192 kDa
Western blot - Anti-KALRN antibody (ab52012)
4
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Our Abpromise to you: Quality guaranteed and expert technical support
Replacement or refund for products not performing as stated on the datasheet
Valid for 12 months from date of delivery
Response to your inquiry within 24 hours
We provide support in Chinese, English, French, German, Japanese and Spanish
Extensive multi-media technical resources to help you
We investigate all quality concerns to ensure our products perform to the highest standards
If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise,
please visit http://www.abcam.com/abpromise or contact our technical team.
Terms and conditions
Guarantee only valid for products bought direct from Abcam or one of our authorized distributors
5